FDA Grants Fast Track Designation for CLR 131 in LPL/WM

The FDA granted fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom ’s macroglobulinemia in patients having received 2 prior treatment regimens or more.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news